From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions

被引：28

作者：

Wu, Manqing ^{[1
]}

Shen, Jun ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes,Ren Ji Ho, Key Lab Gastroenterol & Hepatol,Sch Med,Shanghai, Div Gastroenterol & Hepatol,Shanghai Canc Inst,Mi, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

基金：

中国国家自然科学基金;

关键词：

super-enhancer; non-coding RNA; cell identity; immune checkpoint; cancer; autoimmune disease; LONG-RANGE INTERACTION; CELL IDENTITY; PD-L1; EXPRESSION; SIGNALING PATHWAYS; GENE-EXPRESSION; T-CELLS; CANCER; CHROMATIN; TRANSCRIPTION; INHIBITION;

D O I：

10.3389/fonc.2019.01307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Super-enhancers (SEs) are clusters of enhancers that play a key role in regulating genes that determine cell identity. Enhancer RNAs (eRNAs) are non-coding RNAs transcribed from enhancers that function to promote the enhancer's functions via multiple mechanisms, such as recruiting transcription factors to specific enhancers, promoting enhancer-promoter looping, directing chromatin accessibility, interacting with RNA polymerase II and facilitating histone acetylation. Understanding how super-enhancer RNAs (seRNAs) contribute to specific gene regulation has thus become an area of active interest. Immune checkpoint deregulation is one of the key characteristics of tumors and autoimmune diseases, and is also closely related to cell identity. Recent studies revealed a potential pathway for seRNA's involvement in regulating the expression of immune checkpoints. The present study reviews the current knowledge of eRNA function, immune checkpoint blockage mechanism, and its effect. In addition, for the first time, we explore the direct and indirect roles of seRNAs in regulating immune checkpoint expression in cancer and autoimmune diseases.

引用

页数：16

共 122 条

[1] Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports [J].

Abdel-Wahab, Noha ;

Shah, Mohsin ;

Suarez-Almazor, Maria E. .

PLOS ONE, 2016, 11 (07)

[2] SnapShot: Immune Checkpoint Inhibitors [J].

Abril-Rodriguez, Gabriel ;

Ribas, Antoni .

CANCER CELL, 2017, 31 (06)

[3] BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency [J].

Afzali, Behdad ;

Gronholm, Juha ;

Vandrovcova, Jana ;

O'Brien, Charlotte ;

Sun, Hong-Wei ;

Vanderleyden, Ine ;

Davis, Fred P. ;

Khoder, Ahmad ;

Zhang, Yu ;

Hegazy, Ahmed N. ;

Villarino, Alejandro V. ;

Palmer, Ira W. ;

Kaufman, Joshua ;

Watts, Norman R. ;

Kazemian, Majid ;

Kamenyeva, Olena ;

Keith, Julia ;

Sayed, Anwar ;

Kasperaviciute, Dalia ;

Mueller, Michael ;

Hughes, Jason D. ;

Fuss, Ivan J. ;

Sadiyah, Mohammed F. ;

Montgomery-Recht, Kim ;

McElwee, Joshua ;

Restifo, Nicholas P. ;

Strober, Warren ;

Linterman, Michelle A. ;

Wingfield, Paul T. ;

Uhlig, Holm H. ;

Roychoudhuri, Rahul ;

Aitman, Timothy J. ;

Kelleher, Peter ;

Lenardo, Michael J. ;

O'Shea, John J. ;

Cooper, Nichola ;

Laurence, Arian D. J. .

NATURE IMMUNOLOGY, 2017, 18 (07) :813-+

[4] 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC [J].

Ahmadiyeh, Nasim ;

Pomerantz, Mark M. ;

Grisanzio, Chiara ;

Herman, Paula ;

Jia, Li ;

Almendro, Vanessa ;

He, Housheng Hansen ;

Brown, Myles ;

Liu, X. Shirley ;

Davis, Matt ;

Caswell, Jennifer L. ;

Beckwith, Christine A. ;

Hills, Adam ;

MacConaill, Laura ;

Coetzee, Gerhard A. ;

Regan, Meredith M. ;

Freedman, Matthew L. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (21) :9742-9746

[5] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[6] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].

Alsaab, Hashem O. ;

Sau, Samaresh ;

Alzhrani, Rami ;

Tatiparti, Katyayani ;

Bhise, Ketki ;

Kashaw, Sushil K. ;

Iyer, Arun K. .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[7] The Super-Enhancer-Derived alncRNA-EC7/Bloodlinc Potentiates Red Blood Cell Development in trans [J].

Alvarez-Dominguez, Juan R. ;

Knoll, Marko ;

Gromatzky, Austin A. ;

Lodish, Harvey F. .

CELL REPORTS, 2017, 19 (12) :2503-2514

[8] PD1 signal transduction pathways in T cells [J].

Arasanz, Hugo ;

Gato-Canas, Maria ;

Zuazo, Miren ;

Ibanez-Vea, Maria ;

Breckpot, Karine ;

Kochan, Grazyna ;

Escors, David .

ONCOTARGET, 2017, 8 (31) :51936-51945

[9] Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants [J].

Aune, T. M. ;

Crooke, P. S., III ;

Patrick, A. E. ;

Tossberg, J. T. ;

Olsen, N. J. ;

Spurlock, C. F., III .

JOURNAL OF AUTOIMMUNITY, 2017, 81 :99-109

[10] Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].

Azuma, K. ;

Ota, K. ;

Kawahara, A. ;

Hattori, S. ;

Iwama, E. ;

Harada, T. ;

Matsumoto, K. ;

Takayama, K. ;

Takamori, S. ;

Kage, M. ;

Hoshino, T. ;

Nakanishi, Y. ;

Okamoto, I. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940

← 1 2 3 4 5 6 7 8 9 10 →